DV
Dividend Vision

CYCN — Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. (CYCN)

Total return is -98.5% over the past 7.4 years, 304.5 points behind SPY at 206.0%. Its deepest 1-year drawdown was 66.8%.

Cyclerion Therapeutics, Inc. is an equity stock that focuses on biopharmaceutical development rather than functioning as a traditional dividend ETF. The security does not currently distribute dividends and carries no associated expense ratio data typical of fund structures. This security appeals primarily to growth-oriented investors interested in the therapeutic development sector rather than those seeking regular income distributions.

CYCN key facts

Asset type
Stock
Asset class
Equity
Inception date
03/18/2019
Distribution frequency
None
Last close
$3.79
Market cap
$16,411,890
Average volume
24200.0
Beta
1.747
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.66